Keywords
Pharmacokinetics
Gene therapy
Non-factor therapy
Hemophilia
Categories
How to Cite
Abstract
Background: Hemophilia A and B are inherited bleeding disorders in which outcomes are shaped by factor levels, inhibitor development, inter-individual pharmacokinetics, and progressive joint disease. With the emergence of extended half-life therapies, non-factor therapies, and gene therapy, there is an increasing need for biomarkers to support diagnosis, risk stratification, treatment selection, and monitoring.
Methods: We conducted a narrative review of English-language studies indexed in PubMed, Scopus, Web of Science, and Google Scholar (January 2000 to October 2025). We prioritized primary studies, trials, registries, and assay-validation reports on diagnostic, prognostic, predictive, or monitoring biomarkers in hemophilia A/B; guidelines were used for context.
Results: Established biomarkers include FVIII/FIX activity assays, inhibitor testing (Bethesda/Nijmegen-modified), F8/F9 genotyping, and imaging-based joint assessment. Emerging candidates include global hemostasis assays (thrombin generation, viscoelastic testing), PK/PD metrics for prophylaxis individualization, and exploratory inflammatory/angiogenic and tissue-turnover markers linked to arthropathy.
Conclusions: Evidence for biomarkers in hemophilia is heterogeneous, and many non-traditional markers remain exploratory; standardized assays and prospective multicenter validation with clinically meaningful endpoints are needed before routine adoption. Limitation: This narrative synthesis was conducted in English and did not include a formal risk-of-bias assessment.
References
1. Badulescu OV, Scripcariu DV, Badescu MC, Ciocoiu M, Vladeanu MC, Plesoianu CE, Bojan A, Iliescu-Halitchi D, Tudor R, Huzum B, Frasinariu OE, Bararu-Bojan I. Biomarkers Involved in the Pathogenesis of Hemophilic Arthropathy. Int J Mol Sci. 2024: [PMID: 39337384, https://doi.org/10.3390/ijms25189897]
2. Kalebota N, Novak R, Hrkac S, Peric P, Salai G, Mocibob M, Pranjic M, Zdrahal Z, Pustka V, Zerjavic NL, Milosevic M, Vodanovic M, Salek SZ, Grgurevic L. Proteomic exploration of potential blood biomarkers in haemophilic arthropathy. Health Sci Rep. 2024: e70046 [PMID: 39323462, https://doi.org/10.1002/hsr2.70046]
3. Omer E, Abdulrahman I. Abstracts from the 6th Annual Conference of Emirates Society of Internal Medicine (ESIM) 2025. BMC Proc. 2026: 38 [PMID: 41501744, https://doi.org/10.1186/s12919-025-00352-2]
4. Sarmiento Doncel S, Diaz Mosquera GA, Cortes JM, Agudelo Rico C, Meza Cadavid FJ, Pelaez RG. Haemophilia A: A Review of Clinical Manifestations, Treatment, Mutations, and the Development of Inhibitors. Hematol Rep. 2023: 130 [PMID: 36810557, https://doi.org/10.3390/hematolrep15010014]
5. Jiang D, Wang M, Wheeler AP, Croteau SE. 2025 Clinical Trials Update on Hemophilia, VWD, and Rare Inherited Bleeding Disorders. Am J Hematol. 2025: 666 [PMID: 39901862, https://doi.org/10.1002/ajh.27602]
6. Ni Ainle F, DiMichele D, Falck-Ytter Y, Smit C, De Paula EV, Seth T, Chuansumrit A, Middeldorp S. ISTH clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology: considerations for practice management and implementation. J Thromb Haemost. 2024: 2404 [PMID: 38908829, https://doi.org/10.1016/j.jtha.2024.06.002]
7. Rodriguez-Merchan EC. Serological biomarkers in hemophilic arthropathy: Can they be used to monitor bleeding and ongoing progression of blood-induced joint disease in patients with hemophilia? Blood Rev. 2020: 100642 [PMID: 31796337, https://doi.org/10.1016/j.blre.2019.100642]
8. Lundin B, Manco-Johnson ML, Ignas DM, Moineddin R, Blanchette VS, Dunn AL, Gibikote SV, Keshava SN, Ljung R, Manco-Johnson MJ, Miller SF, Rivard GE, Doria AS, International Prophylaxis Study G. An MRI scale for assessment of haemophilic arthropathy from the International Prophylaxis Study Group. Haemophilia. 2012: 962 [PMID: 22765835, https://doi.org/10.1111/j.1365-2516.2012.02883.x]
9. About Biomarkers and Qualification [Internet]2025 [cited 2025].
10. Califf RM. Biomarker definitions and their applications. Exp Biol Med (Maywood). 2018: 213 [PMID: 29405771, https://doi.org/10.1177/1535370217750088]
11. Karapnar TH, Karadas N, Ozek G, Tufekci O, Atabay B, Turker M, Yuksel F, Karapinar DY, Vergin C, Irken G, Oren H. The investigation of relationship between joint findings and serum angiogenic and inflammatory factor levels in severe hemophilia A patients. Blood Coagul Fibrinolysis. 2014: 703 [PMID: 24850210, https://doi.org/10.1097/MBC.0000000000000131]
12. Manon-Jensen T, Tangada S, Bager C, Chowdary P, Klamroth R, von Drygalski A, Windyga J, Escobar M, Frederiksen P, Engl W, Ewenstein B, Karsdal M. Evaluation of collagen turnover biomarkers as an objective measure for efficacy of treatment with rurioctocog alfa pegol in patients with hemophilia A: a secondary analysis of a randomized controlled trial. J Thromb Haemost. 2024: 90 [PMID: 37717853, https://doi.org/10.1016/j.jtha.2023.08.035]
13. Bardi E, Astermark J. Genetic risk factors for inhibitors in haemophilia A. Eur J Haematol. 2015: 7 [PMID: 25560788, https://doi.org/10.1111/ejh.12495]
14. Fan MN, Shen T, Konkle BA, Cai X, Chao TY, Manco-Johnson M, Faino AV, Zhang J, Bao S, Xiao W, Li L, Miao CH. Exploration of biomarkers for inhibitor development in persons with hemophilia A. Res Pract Thromb Haemost. 2025: 102877 [PMID: 40502463, https://doi.org/10.1016/j.rpth.2025.102877]
15. da Conceicao Bezerra AF, Batista-Rodrigues YK, Rezende SM, Souza RP. The role of interleukin-10 gene variants in inhibitor development in hemophilia: A meta-analysis. Thromb Res. 2025: 109427 [PMID: 40815904, https://doi.org/10.1016/j.thromres.2025.109427]
16. Batty P, Watson D, Wozniak E, others. Transcriptomic profiling in severe hemophilia A patients with inhibitors identifies up-regulated B-cell markers (abstract). 2023.
17. Kaya Z, KİRkİZ S, Albayrak M, GÜNey E, Aytac S, ÖZbek NY. Adherence to Prophylaxis in Relation to Quality of Life and Anxiety Level in Turkish Patients with Severe Haemophilia A. International Journal of Health Services Research and Policy. 2020: 194 https://doi.org/10.33457/ijhsrp.738665]
18. Lopez-Jimenez JJ, Ortega-Cervantes R, Luna-Zaizar H, Fletes-Rayas AL, Beltran-Miranda CP, Troyo-Sanroman R, Soto-Padilla J, Tlacuilo-Parra A, Jaloma-Cruz AR. Genetic biomarkers related to hemarthrosis, inflammation, and cartilage structure in pediatric patients with hemophilic arthropathy. Mol Genet Genomic Med. 2019: e979 [PMID: 31566926, https://doi.org/10.1002/mgg3.979]
19. Pulles AE, Mastbergen SC, Foppen W, Schutgens REG, Lafeber F, van Vulpen LFD. The combination of urinary CTX-II and serum CS-846: Promising biochemical markers to predict radiographic progression of haemophilic arthropathy-An exploratory study. Haemophilia. 2018: e278 [PMID: 30044054, https://doi.org/10.1111/hae.13554]
20. van Vulpen LF, van Meegeren ME, Roosendaal G, Jansen NW, van Laar JM, Schutgens RE, Mastbergen SC, Lafeber FP. Biochemical markers of joint tissue damage increase shortly after a joint bleed; an explorative human and canine in vivo study. Osteoarthritis Cartilage. 2015: 63 [PMID: 25219667, https://doi.org/10.1016/j.joca.2014.09.008]
21. Aghighi S, Riddell A, Lee CA, Brown SA, Tuddenham E, Chowdary P. Global coagulation assays in hemophilia A: A comparison to conventional assays. Res Pract Thromb Haemost. 2020: 298 [PMID: 32110761, https://doi.org/10.1002/rth2.12295]
22. Hermans C, Astermark J, Trakymiene SS, Jimenez-Yuste V. Haemophilia B: an illustrative review of current challenges and opportunities. Res Pract Thromb Haemost. 2025: 103229 [PMID: 41322967, https://doi.org/10.1016/j.rpth.2025.103229]
23. Pasta G, Annunziata S, Polizzi A, Caliogna L, Jannelli E, Minen A, Mosconi M, Benazzo F, Di Minno MND. The Progression of Hemophilic Arthropathy: The Role of Biomarkers. Int J Mol Sci. 2020: [PMID: 33023246, https://doi.org/10.3390/ijms21197292]
24. Zhang WT, Wang YJ, Yao YF, Zhang GX, Zhang YN, Gao SS. Circulating microRNAs as potential biomarkers for the diagnosis of Parkinson's disease: A meta-analysis. Neurologia (Engl Ed). 2024: 573 [PMID: 39232595, https://doi.org/10.1016/j.nrleng.2024.07.004]
25. Leuci A, Marano M, Millet M, Lienhart A, Desage S, Chapurlat R, Dargaud Y. Deciphering the circulating microRNA signature of hemophilic arthropathy. Thromb Res. 2024: 109099 [PMID: 39079229, https://doi.org/10.1016/j.thromres.2024.109099]
26. Sidonio RF, Jr., Hoffman M, Kenet G, Dargaud Y. Thrombin generation and implications for hemophilia therapies: A narrative review. Res Pract Thromb Haemost. 2023: 100018 [PMID: 36798897, https://doi.org/10.1016/j.rpth.2022.100018]
27. Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Valente N, Asikanius E, Levy GG, Windyga J, Shima M. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017: 809 [PMID: 28691557, https://doi.org/10.1056/NEJMoa1703068]
28. Hermans C, Noone D, Benson G, Dolan G, Eichler H, Jimenez-Yuste V, Konigs C, Lobet S, Pollard D, Zupancic-Salek S, Mancuso ME. Hemophilia treatment in 2021: Choosing the"optimal" treatment using an integrative, patient-oriented approach to shared decision-making between patients and clinicians. Blood Rev. 2022: 100890 [PMID: 34736780, https://doi.org/10.1016/j.blre.2021.100890]
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 Dalia Atef Abouda, Elsayed S. Moubarak, Fatma ElBadrawy , Malak A. Hassan, Mohamed Mohsen Helal, Abdallah M. Ibrahim , Hassan H. Eladl, Mohammad Mahadin , Mohamed Elsaid